HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Raloxifene (Evista)

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Also Known As:

Evista; ELi Lilly Brand of Raloxifene; Keoxifene; Keoxifene Hydrochloride; LY 139481; LY 156758; LY-139481; LY-156758; Lilly Brand of Raloxifene; Raloxifene Hydrochloride; LY139481; LY156758; Raloxifene Lilly Brand; Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)-

Networked: 1402 relevant articles (146 outcomes, 434 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Hydrocarbons: 412
  - Cyclic Hydrocarbons: 3
    - Aromatic Hydrocarbons: 132
      - Benzene Derivatives: 13
        Benzylidene Compounds
        Stilbenes: 79
        Tamoxifen: 10496
        Raloxifene: 1402
        iodoraloxifene
        raloxifene diphosphate
        Y134 compound

Experts

1.	Jordan, V Craig: 37 articles (05/2013 - 01/2002)
2.	Vogel, Victor G: 29 articles (01/2014 - 06/2002)
3.	Costantino, Joseph P: 17 articles (01/2014 - 06/2002)
4.	Wickerham, D Lawrence: 16 articles (01/2015 - 06/2002)
5.	Wolmark, Norman: 14 articles (01/2015 - 06/2002)
6.	Cummings, Steven R: 14 articles (06/2011 - 01/2002)
7.	Jordan, V C: 14 articles (01/2007 - 01/2000)
8.	Cauley, Jane A: 13 articles (11/2012 - 01/2002)
9.	Barrett-Connor, Elizabeth: 13 articles (08/2009 - 12/2002)
10.	Wong, Mayme: 12 articles (08/2010 - 01/2002)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 01/01/2004 - "Completion of these trials will provide important information about the occurrence of invasive breast cancer in postmenopausal women and the efficacy of raloxifene for breast cancer risk reduction." 01/01/2004 - "It seems clear that raloxifene increases bone mineral density, has no effect on the endometrium, and holds high promise for the prevention of breast cancer. " 06/15/2001 - "The women with the highest BMD and those with a family history of breast cancer experienced a significantly greater therapy benefit with raloxifene, compared with the two thirds of patients with lower BMD or those without a family history, respectively; the subgroup-by-therapy interactions were significant (P =.005 and P =.015, respectively). " 12/01/2003 - "Raloxifene therapy was also associated with a favorable or neutral effect in the cardiovascular system, and a reduced incidence of breast cancer. " 05/01/2008 - "Different placebo-controlled trials indicated that raloxifene is effective in reducing invasive breast cancer risk in postmenopausal women. "
2.	Osteoporosis 07/01/2007 - "In postmenopausal women with osteoporosis, low-dose HRT produced significantly greater increases in BMD of the lumbar spine and total body and greater decreases in bone turnover than raloxifene at 12 months." 02/01/2006 - "The definite anti-fracture efficacy of raloxifene at the spine, its plausible effect on non-spine fracture in high-risk patients and its beneficial effect on breast and heart make this compound an interesting approach for women presenting with osteoporosis. " 01/01/2006 - "In conclusion, raloxifene treatment at 60 mg/day for 1 year resulted in a significant reduction in the risk of new clinical vertebral fractures and any new clinical fracture in postmenopausal Asian women with osteoporosis." 03/01/2006 - "The Multiple Outcomes of Raloxifene Evaluation (MORE) trial of women with osteoporosis has described the efficacy of raloxifene in decreasing vertebral fracture risk over 4 years. " 08/01/2000 - "In randomised placebo-controlled studies involving postmenopausal women or patients with osteoporosis, raloxifene 60 to 150 mg/day was effective in increasing bone mineral density (BMD) over 12- to 36-month periods. "
3.	Postmenopausal Osteoporosis 03/01/2010 - "Raloxifene shows the significant improvement of the index of resistance to bending forces (section modulus) in Japanese patients with postmenopausal osteoporosis. " 01/01/2000 - "Raloxifene is effective in preventing bone loss and may prevent fractures in postmenopausal osteoporosis. " 01/01/2010 - "Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update." 11/01/2012 - "This prospective, postmarketing observational study was conducted at 60 Japanese hospitals from September 2007 to February 2009 and included Japanese women with postmenopausal osteoporosis who were new to standard treatment with raloxifene (60 mg/day). " 11/01/2012 - "Quality of life in raloxifene-treated Japanese women with postmenopausal osteoporosis: a prospective, postmarketing observational study."
4.	Neoplasms (Cancer) 07/01/2003 - "The patients had a significant response to raloxifene therapy, with complete remission in 8 cases and partial response in 5 cases, evaluated by regression of symptoms and tumor size. " 02/01/2014 - "These data suggest that cervical cancer cells are not completely eradicated by raloxifene and rapidly expand if raloxifene treatment is ceased. " 01/01/2009 - "Our findings suggest that ER-beta acts as a colon tumor promoter and raloxifene as an antagonist to ER-beta, providing protection against colon carcinogenesis." 09/01/2013 - "This study demonstrates that raloxifene (0.85 mg/kg) prevents TNBC tumor growth and induces tumor regression. " 01/01/2013 - "These studies underline the unique role of extranuclear ERα in E2- and raloxifene-induced tumor regression that may have implications for treatment of endocrine-resistant PKCα-expressing tumors encountered in the clinic."
5.	Schizophrenia (Dementia Praecox) 10/01/2015 - "Younger patients diagnosed as treatment-resistant schizophrenia and treated with raloxifene (120 mg/day) have reported significant improvement in symptoms. " 11/01/2011 - "If more extensive and longer-term studies confirm and expand upon these positive results, the use of raloxifene could be recommended in postmenopausal patients with schizophrenia. " 10/01/2015 - "Raloxifene augmentation in postmenopausal women with schizophrenia has shown promising results. " 06/01/2015 - "The present study tested the extent to which adjunctive raloxifene treatment improved cognition and reduced symptoms in young to middle-age men and women with schizophrenia. " 01/01/2015 - "The purpose of the present investigation was to assess the efficacy of raloxifene as an adjuvant agent in the treatment of men with chronic schizophrenia in an 8-week double-blind and placebo-controlled trial. "

Related Drugs and Biologics

1.	Tamoxifen
2.	Selective Estrogen Receptor Modulators (SERM)
3.	Estrogens (Estrogen)
4.	Alendronate (Alendronate Sodium)
5.	Estradiol (Estrace)
6.	bazedoxifene acetate
7.	Raloxifene (Evista)
8.	risedronic acid (risedronate)
9.	Diphosphonates
10.	tartrate salt cis- 1R- (4'- pyrrolidinoethoxyphenyl)- 2S- phenyl- 6- hydroxy- 1,2,3,4- tetrahydronaphthalene (Lasofoxifene)

Related Therapies and Procedures

1.	Chemoprevention
2.	Hysterectomy
3.	Estrogen Replacement Therapy
4.	Drug Therapy (Chemotherapy)
5.	Oral Administration